Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Argenta and ANTABIO Announce Drug Discovery Collaboration

Published: Friday, February 08, 2013
Last Updated: Thursday, February 07, 2013
Bookmark and Share
Programme will focus on novel antibacterial agents.

Argenta has announced that it has signed a collaboration agreement with ANTABIO.

Under the terms of the agreement, Argenta will provide medicinal chemistry, computer-aided drug design and ADME/PK services, together with its integrated drug discovery expertise, to assist ANTABIO in the identification of novel anti-bacterial agents and discovery of a development candidate that can be progressed into clinical trials.

The collaboration is funded by a Wellcome Trust Seeding Drug Discovery award.

Between 5 and 10% of hospital patients in the US and Europe develop hospital-acquired (nosocomial) infections. The consequences are up to 75,000 deaths per year, 2.5 million additional hospital days due to drug-resistant bacterial infections and an average additional cost of 1.5 billion euros for healthcare systems.

In 2004, the World Health Organization identified infections caused by drug-resistant bacteria as the number one disease requiring priority medicines.

ANTABIO’s first-in-class, small molecule compounds offer a synergistic solution to the shortfall of current antibacterial agents.

In particular, ANTABIO is developing new drugs that will work with existing antibiotics to enable them to regain their activity against multi- or pan-drug resistant Gram-negative pathogens such as NDM-1 bacteria.

ANTABIO’s compounds will also prevent infections caused by virulent and multi-drug resistant bacteria such as Escherichia coli (E. coli) that are responsible for severe nosocomial-acquired infections as well as other common community-acquired conditions like urinary tract infections and food poisoning.

Dr John Montana, Managing Director of Argenta, commented, “Argenta is proud to announce this agreement with ANTABIO, which is the second SDDI-funded collaboration to be disclosed by Argenta in recent months. There is an urgent need for new anti-bacterial drugs and we look forward to working with ANTABIO to progress their compounds rapidly towards pre-clinical candidate nomination”.

“We are very excited to collaborate with Argenta on this SDDI-funded programme” said Dr Marc Lemonnier, CEO of ANTABIO.

Dr Lemonnier continued, “Assembling an expert and complementary drug discovery team is critical when it comes to advancing novel drugs that are so badly needed by patients suffering from life-threatening infections. This joint effort nicely exemplifies our vision of high-value partnering as a key element to deliver tomorrow’s antibacterial agents”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Argenta Announces Record Year for Peer-Reviewed Publications
Publications have been co-authored with clients such as Genentech, AstraZeneca and Corcept.
Tuesday, December 10, 2013
Argenta Announces Fourth Extension of Drug Discovery Collaboration with Genentech
Agreement covers a portfolio of projects that utilizes Argenta's drug discovery expertise.
Monday, October 14, 2013
Argenta and Pcovery Announce Drug Discovery Collaboration
Under the terms of the agreement, Argenta will provide medicinal chemistry and computer-aided drug design services to assist Pcovery.
Tuesday, July 16, 2013
Argenta in Respiratory Pact with Pulmagen
Subcontracting agreement to perform integrated services on two respiratory projects.
Thursday, July 07, 2011
Scientific News
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Chi-Med Initiates Sulfatinib Phase III Registration Study
Company has initiated SANET-p, a Phase III registration trial of sulfatinib with pancreatic neuroendocrine tumors (“NETs”).
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!